Toronto, Canada

Sunnybrook Research Institute is the research component of Sunnybrook Health science Centre in Toronto, Ontario. It is one of the largest research centres in Canada, second only to the University Health Network within the Toronto Academic Health science Centre Network. SRI is fully affiliated with the University of Toronto.Conducting over $100 million in research every year, SRI is home to a number of breakthroughs that have transformed health care. The research institute supports the activities of over 200 scientists and clinician-scientists, over 200 research associates, engineers, physicists and technicians and over 300 students and trainees that works in 250,000 square feet of state-of-the-art research space in northeastern Toronto. They work to prevent disease and develop treatments that enhance and extend life. These aims derive from SRI’s core vision: to achieve discovery and its translation into clinic to set best practices. Wikipedia.


Time filter

Source Type

Patent
Spidertech Inc. and Sunnybrook Research Institute | Date: 2015-08-21

A wound care tape includes a sterile high-stretch strip of woven material having a first face and an opposed second face. A sterile adhesive is on the first face in a discontinuous pattern, whereby a set of spaced apart adhesive-covered portions of the first face are covered by the adhesive, and a set of spaced apart adhesive-free portions of the first face are free of the adhesive.


Patent
Novartis and Sunnybrook Research Institute | Date: 2016-10-12

The present invention relates to a method of treating breast cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a breast cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3,4:6,7] indolizino [1,2-b]quinoline-3,14-(4H,12H)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof.


Patent
Colibri Inc. and Sunnybrook Research Institute | Date: 2014-03-14

Systems and methods are provided for localizing and visualizing devices with the use of an intracorporeal ultrasound imaging probe during a medical procedure. A primary intracorporeal ultrasound imaging probe is employed to image a three-dimensional region via scanning, and to locate a secondary intracorporeal device having one or more ultrasonic beacon transducers. When an A-scan vector associated with the primary intracorporeal ultrasound imaging device is directed towards one or more of the ultrasound beacon transducers of the secondary intracorporeal device, a communication signal is transmitted from the secondary intracorporeal device to a control and processing system associated with the primary intracorporeal ultrasound imaging device, either through acoustic transmission or non-acoustic transmission. Example embodiments are provided in which acoustic communication may be employed within the imaging band, or in a separate communication band distinct from the communication band. Various example dual-band, single-stack ultrasound imaging transducer embodiments are disclosed.


High-dose glucocorticoids (GCs) can be a useful treatment for aggressive forms of chronic lymphocytic leukemia (CLL). However, their mechanism of action is not well understood, and resistance to GCs is inevitable. In a minimal, serum-free culture system, the synthetic GC dexamethasone (DEX) was found to decrease the metabolic activity of CLL cells, indicated by down-regulation of pyruvate kinase M2 (PKM2) expression and activity, decreased levels of pyruvate and its metabolites, and loss of mitochondrial membrane potential. This metabolic restriction was associated with decreased size and death of some of the tumor cells in the population. Concomitant plasma membrane damage increased killing of CLL cells by DEX. However, the nuclear receptor peroxisome proliferator activated receptor α (PPARα), which regulates fatty acid oxidation, was also increased by DEX, and adipocyte-derived lipids, lipoproteins, and propionic acid protected CLL cells from DEX. PPARα and fatty acid oxidation enzyme inhibitors increased DEX-mediated killing of CLL cells in vitro and clearance of CLL xenografts in vivo. These findings suggest that GCs prevent tumor cells from generating the energy needed to repair membrane damage, fatty acid oxidation is a mechanism of resistance to GC-mediated cytotoxicity, and PPARα inhibition is a strategy to improve the therapeutic efficacy of GCs.


Kerbel R.S.,Sunnybrook Research Institute
Journal of Mammary Gland Biology and Neoplasia | Year: 2012

Viewed as a whole, the aggregate outcomes of a number of positive randomized phase III clinical trial results evaluating the VEGF-pathway targeting antiangiogenic drug bevacizumab, with or without concurrent chemotherapy, in metastatic breast cancer patients have been disappointingly modest. In the case of antiangiogenic tyrosine kinase inhibitors (TKIs) the results have been negative. Nevertheless, several findings indicate antiangiogenic drugs, especially bevacizumab, are active and can lead to demonstrable clinical benefit in some patients, thus stimulating research into developing strategies to significantly improve their efficacy and reduce toxicity. Some of these initiatives include: 1) discovery and validation of predictive markers that can prospectively identify patients more likely to benefit from antiangiogenic therapy; 2) recognition that the nature of the chemotherapy partner or backbone can strongly impact outcomes when combined with antiangiogenic drugs such as bevacizumab, and thus developing what may be improved combination chemotherapy partner regimens, e.g. metronomic chemotherapy; 3) evaluating prospectively in more depth whether subtypes of the disease - especially triple negative or inflammatory breast cancer - are more responsive to antiangiogenic therapy than other subtypes; 4) evaluating new agents that inhibit angiogenesis in a VEGF-independent manner and other types of drug that can be effectively combined with antiangiogenics, e.g. c-met inhibitors; 5) uncovering the basis of resistance or relapse/progression on the therapy with antiangiogenic drugs; 6) development of improved predictive preclinical breast cancer models for therapy testing, e.g. treatment of mice with established multi-organ breast cancer metastatic disease or genetically engineered mouse models of breast cancer, or mice bearing patient derived breast cancer tissue xenografts. © 2012 Springer Science+Business Media, LLC.


Patent
Sunnybrook Research Institute | Date: 2016-06-15

Intravascular imaging catheters are provided that include a distal sheath portion having a lumen that is configured to optionally receive a guidewire or an imaging assembly. The distal sheath portion may be configured to have dimensions such that when a guidewire is inserted through the lumen and extends through a distal exit port, the distal sheath portion may be employed as a microcatheter. External tissue may be imaged at a location at or near the distal end of the catheter, enabling, for example, the controlled imaging of a total occlusion, and the positioning of the distal end (and guidewire) within a true lumen associated with a total occlusion. A structural stop may be provided at or near the distal end of the distal sheath portion to prohibit extension of the imaging assembly out of the distal exit port, while permitting the extension of the guidewire through the distal exit port.


Patent
Sunnybrook Research Institute | Date: 2015-02-26

A system and method for performing a medical procedure is provided. The system includes a device having a shaft that generally extends from a proximal end to a distal end along a longitudinal axis. The distal end of the device is configured to identify a topographical profile of a lumen, wherein the topographical profile is determined by traversing the device a distance along the longitudinal axis of the lumen. The device also includes at least one of a plurality of projections movably coupled to the distal end and configured to provide a coupling with the lumen by extending in a direction substantially orthogonal to the longitudinal axis, and at least one radiopaque marker coupled to the distal end and designed to provide a contrast during imaging of the device.


Patent
Sunnybrook Research Institute | Date: 2014-03-14

A system and method for measuring volumetric breast density using a low dose of radiation are provided. This low-dose image can be added to a standard mammographic screening protocol with less than a two percent increase in radiation dose imparted to the subject. This low-dose image can also be used as a single standalone test to determine breast density for younger women for the purposes of risk determination or screening regimen planning The breast density measurement is more accurate than measurements that can be obtained with existing systems and methods by making use of a compression assembly that maintains a parallel alignment between the compression paddle and breast support table. Additionally, the compression assembly maintains a uniform known thickness of the compressed breast. The system and method have the added benefit that they can be readily implemented on a conventional digital x-ray unit with low cost.


Patent
Sunnybrook Research Institute | Date: 2016-04-05

The present application provides a multilayer lateral mode coupling method for phased array construction and transducer devices built accordingly. This disclosure describes and demonstrates that the electrical impedance of a phased array can be substantially reduced and readily controlled to be close to the source impedance. The fabrication process is relatively simple and inexpensive. In addition, the elements are robust for use in 1.5, 2, 3 or other dimensional configurations, over an extended period of operation, without structural failure, and providing a high power output required for imaging and/or medical therapy applications.


Patent
Sunnybrook Research Institute | Date: 2014-04-08

Described here are systems and methods for visualizing thermal ablation lesions by imaging specific chemical compounds that are created during thermal ablation procedures, such as cardiac ablation procedures. When a cardiac ablation procedure is performed, a central area of coagulative necrosis is created at the treatment site. This necrotic region is surrounded by layers of tissues with ultra-structural and electrophysiological changes. Two particular changes include the denaturation of proteins and the formation of ferric iron containing chemical compounds, such as methemoglobin and metmyoglobin. The formation of and distribution of such chemical compounds can be imaged with the appropriate systems and methods. Accordingly, these chemical compounds can be utilized as biomarkers that indicate the presence and physical characteristics of thermal ablation lesions. Imaging can be performed using magnetic resonance imaging, optical imaging, or photoacoustic imaging, as examples.

Loading Sunnybrook Research Institute collaborators
Loading Sunnybrook Research Institute collaborators